The technology is a patented oral delivery platform, offering a combination of gastric protection and controlled release
Lallemand Health Solutions and Aventus Innovations have signed a global agreement to grant Lallemand exclusive use of Aventus’ NutraJIT technology for probiotic applications. The technology is a patented oral delivery platform, offering a combination of gastric protection and controlled release particularly suitable for active ingredients like probiotics. It has already been tested and used, the company said, to protect other ingredients, like melatonin, vitamins, and certain minerals.
“As a young innovative Canadian company which develops oral delivery technologies intended for use by dietary supplements companies like Lallemand Health Solutions, we are thrilled to have concluded this agreement which will allow our ingredients to serve consumers, worldwide” said Nicolas Kronström, COO at Aventus Innovations.
“This protective technology is efficient on both capsules and tablets, which is a great addition to our existing portfolio. NutraJIT is a versatile vehicle for active ingredients to make their way to their site of action, without being affected by the stomach fluids acidity and with reduced gastric side effects.” said Marie-Eve Boyte, Scientific Affairs Director at Lallemand Health Solutions.
NutraJIT is a derivative of food-product protein and is all-natural, allergen-free and clean label, Aventus says. It creates a gel barrier in a low pH environment, protecting the probiotic formula from stomach acidity. When reaching the intestines, it desegregates as the pH is increasing, releasing the bacteria where they need to be.
“We are eager to bring this new attractive solution to the probiotic market and are actively preparing the launch for the coming fall.” added Bérengère Feuz, Marketing Director at Lallemand Health Solutions.